| 6.32 0.11 (1.77%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.7 |
1-year : | 9 |
| Resists | First : | 6.59 |
Second : | 7.7 |
| Pivot price | 5.58 |
|||
| Supports | First : | 5.14 |
Second : | 4.24 |
| MAs | MA(5) : | 5.95 |
MA(20) : | 5.37 |
| MA(100) : | 6.67 |
MA(250) : | 5.87 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 87.9 |
D(3) : | 83.7 |
| RSI | RSI(14): 60.1 |
|||
| 52-week | High : | 9.82 | Low : | 3.27 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ VRCA ] has closed below upper band by 13.6%. Bollinger Bands are 13.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.6 - 6.62 | 6.62 - 6.65 |
| Low: | 6.15 - 6.18 | 6.18 - 6.2 |
| Close: | 6.28 - 6.31 | 6.31 - 6.35 |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Fri, 17 Apr 2026
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Reduce" by Brokerages - MarketBeat
Thu, 09 Apr 2026
Skin cancer drug data from Verrica wins late-breaker slot in Chicago - Stock Titan
Thu, 09 Apr 2026
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to Strong Sell at Zacks Research - MarketBeat
Mon, 06 Apr 2026
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Mon, 06 Apr 2026
Needham conference adds Verrica CEO; webcast runs live April 15 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 6.78e+006 (%) |
| Held by Institutions | 48.2 (%) |
| Shares Short | 385 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.145e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -50.3 % |
| Operating Margin | -136.5 % |
| Return on Assets (ttm) | -14.8 % |
| Return on Equity (ttm) | -240.4 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 260.41 |
| Sales Per Share | 2.43699e+007 |
| EBITDA (p.s.) | 1.59452e+007 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 6.4 |
| Dividend | 0 |
| Forward Dividend | 478580 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|